Boulder, Colorado-based Source MDx has launched a new set of oncology biomarker services for cancer therapty development. The firm said that it will provide profiling of live Circulating Tumor Cells (CTCs) and Circulating Endothelial Cells (CECs), used for targeted gene assays. Source MDx said that the new services are aimed at providng pharmaceutical and biotech companies with a more targeted approach to development of cancer therapies.
Top NewsFriday, September 15, 2006
Source MDx Launches Biomarker Service